As you will know, the Josep Carreras Foundation and Institute Christmas dinner was held on 22 December. It's the first time we've all had Christmas dinner together and we were very pleased with it because it's a way for everyone—the members of the different campuses, the Foundation and IJC staff, scientists and others—to get to know each other better. Wherever we are and wherever we work we all form an active part of the struggle against leukaemia and with every year that passes the team gets bigger and bigger. Thank you for being part of that team! You can see photos of the dinner here
JOSEP CARRERAS LEUKAEMIA RESEARCH INSTITUTE (IJC)
3rd Josep Carreras Leukaemia Research Institute Scientific Meeting
The 3rd Josep Carreras Leukaemia Research Institute Scientific Meeting was held on 15 January at the IJC Sant Pau Campus. It was attended by over 70 people, amongst them IJC scientific directors, lead researchers and pre- and post-doctoral fellows. You can consult the symposium programme here. And here are some of the photos taken at the event.
New resources for one of the ALL teams
One of the research projects into acute lymphoblastic leukaemia (ALL), a project being carried out by Dr. Josep Maria Ribera from the Catalan Institute for Oncology/Germans Trias i Pujol Campus, has been awarded a €34,220 grant by the biopharmaceutical company Gilead Espanya.
The aim of the project, entitled Next Generation Sequencing versus high sensitivity flow cytometry for the detection of residual disease in childhood and adult acute lymphoblastic leukemia is to establish whether a new genetic technique will make it possible to more precisely determine the amount of leukaemia remaining in the organism after initial treatment. This would help in assessing and applying any further treatment such as chemotherapy or the transplant of hematopoietic precursors.
The IJC at the American Society of Hematology (ASH)
The 57th American Society of Hematology Congress (ASH), held last December in Orlando, was attended by many researchers from the IJC. We would like, however, to draw special attention to the contribution made by Verà Ademà from the myelodysplastic syndromes group at the Catalan Institute for Oncology/Germans Trias i Pujol Campus of the IJC. The project presented was: The complete mutatome and clonal architecture of del(5q). Itis an international study being undertaken by groups in Europe and the United States involving 220 patients with myelodysplastic syndrome or acute myeloid leukaemia characterised by 5q deletion in conventional cytogenetics. Normal and cancer genomes were sequenced in order to identify possible genes that might predict the response or resistance to treatment as well as the evolution of the disease. Congratulations Vera for this presentation!
Rising to the Challenge of VOD: Advances in Care for the Transplant patient
Dr. Enric Carreras, member of the Foundation and of the IJC, took part, together with other international specialists, in a symposium on treatment for patients undergoing bone marrow transplants. The symposium was held under the auspices of the U.S. Institute for Continuing Medical Education (Medical Learning Institute and PVI, PeerView Institute for Medical Education). We invite you to read the document here.
Dr. Albert Oriol publishes a new article in The Lancet about improving treatment for patients with multiple myeloma
Daratumumab is the name of the drug that Dr. Albert Oriol, together with colleagues from the United States and Canada, has tested to discover a combination which will delay relapse in those patients with multiple myeloma who do not respond to established treatments and/or for whom a transplant would not be considered appropriate. The trial, which was conducted with 157 patients, improved both the time of response and tolerance to treatment. For more information the paper can be found here.
What is going on between defibrotide and endothelial cells? Snapshots reveal the hot spots of their romance.
This is the encouraging title of the paper published recently in the journal Blood by the IJC Barcelona Endothelium Team (BET). Defibrotide (DF) has been given authorisation by the European Medicines Agency (EMA)to treat Sinusoidal Obstruction Syndrome, a frequent complication after the transplant of hematopoietic cells. DF has a recognised role as an endothelial protector although the precise mechanism through which it does this is not fully known. The aim of the present study is to investigate the interaction of DF with endothelial cells. The results contribute to a better understanding of the precise mechanisms by which DF acts as a therapeutic and potentially preventive agent on the endothelial damage underlying different pathological situations. + info: Pubmed. + info Journal Blood
Leukos Biotech capital increase
The Josep Carreras Foundation now forms part of the scientific startup Leukos Biotech with a majority 70% shareholding. This new injection of funds has made it possible to contract a member of staff to prepare everything needed to request further funding in order to complete the necessary studies before commencing on Phase 2 of the clinical trials. + info about Leukos Biotech.
RNA Congress at the Centre for Genomic Regulation
On account of RNA's increasing importance in the field of biology and its association with cancer the IJC decided to organise a second international conference on this subject to bring together renowned scientists in the fields of RNA biology and related diseases. The conference was jointly organised by the RNAREG consortium and the Josep Carreras Leukaemia Research Institute (IJC) and focussed on current topics in the field of molecular biology. A very successful and similar event was organised in 2012. The conference was organised mainly by Dr. Mayka Sánchez from the Catalan Institute for Oncology/Germans Trias i Pujol Campus (ICO-GTiP) and it was attended by approximately 300 people from around the world. Renowned speakers included Prof. Dr. Andreas Kulozik, Director of MMPU Heidelberg, Germany, Prof. Dr. Myriam Gorospe, chief researcher, USA, and Prof. Dr. Joel Richter, Co-director of the Center for Collaborative Research in Fragile X, UMass, USA.
The latest Bone Marrow Donor Registry (REDMO) magazine is out now and in it you will find all the latest news about hematopoietic progenitors, the latest figures concerning the increase in bone marrow donors in Spain, opinion and comment, a report on the National Umbilical Cord Blood Plan, articles by patients and donors describing their experiences and much more.
If you are still not a bone marrow donor and you would like more information on the subject, you will find the magazine has a section with a list of the questions most frequently asked by potential donors.
Don't miss this issue of REDMO! Read it here online or download it now! (Spanish or Catalan)
#TODOSJUNTOAMARKELCONTRALALEUCEMIA (everyone together with Markel against leukaemia) is a micro-donation initiative on the Migranodearena.org (MGDA) platform which has raised €8,273 for our Foundation.
It is an initiative by a group of friends in Vitòria to give support to one of them, Markel, who was diagnosed as having leukaemia in August. The idea, by one of Markel's best friends Unai, has taken shape in various ways such as online micro-donations, a solidarity day in a Basque school, and the sale of merchandise.
Everyone who wants to can create a fund-raising event on MGDA to help fight against leukaemia. Thanks to these initiatives we receive a lot of funds and publicity.
The year's first races against leukaemia
The year has started with funds being raised for our projects with the support of Funes (in Navarre) and Ribadesella (in Astúries), where the year's first fund-raising races have been held.
Both towns held a San Silvestre solidarity race with more than 1,000 runners taking part and raising a total of more than €5,000. In both cases it was the first time they had organised a San Silvestre solidarity race and both towns were delighted with the response of the neighbours and runners, as well as with the results. The town councils in both localities lent their logistical support. Donations were raised through runner registration numbers, the sale of T-shirts and in collection-box donations.
Football match to support the fight against leukaemia
Mossos d’Esquadra, members of the Catalan police force, organised a football match and raised €2.810 for our cause by holding a raffle for various sporting items, specially signed for the event by players at Barcelona Football Club, and through a football 7 competition for which players made a donation to be inscribed.